Published on

Pediatrics - Epstein-Barr Virus Infection (Infectious Mononucleosis)

1. BASICS

Description

Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus responsible for infectious mononucleosis and several other acute and chronic clinical syndromes.

EBV is also known as human herpesvirus 4 (HHV-4).

It is an enveloped, double-stranded DNA virus belonging to the family Herpesviridae, subfamily Gammaherpesvirinae.

Clinical Spectrum

EBV infection may produce:

  • Asymptomatic infection.
  • Mild nonspecific febrile illness.
  • Infectious mononucleosis.
  • Hepatitis.
  • Hematological abnormalities.
  • Neurological complications.
  • Lymphoproliferative disease in susceptible individuals.

Infectious Mononucleosis

The classic syndrome is characterized by:

  • Fever.
  • Pharyngitis.
  • Cervical lymphadenopathy.
  • Fatigue.
  • Atypical lymphocytosis.

Hepatosplenomegaly may also occur.

Essential Principle

Most EBV infections in immunocompetent children resolve without specific antiviral treatment, but airway obstruction, splenic rupture, severe cytopenias, and neurological complications require urgent recognition.

2. EPIDEMIOLOGY

Worldwide Distribution

EBV infection occurs throughout the world.

Human Reservoir

Humans are the principal natural reservoir.

Seroprevalence

More than 90% of adults worldwide have evidence of previous EBV infection, although prevalence varies by population.

Childhood Infection

Primary infection frequently occurs during childhood.

Adolescent Infection

A second important period of acquisition occurs during adolescence and young adulthood.

Symptomatic Disease

Primary infection in early childhood is often asymptomatic or mild.

Infectious mononucleosis is more likely when primary infection occurs during adolescence.

Clinical Importance

Age at primary infection strongly influences the likelihood of developing the classic mononucleosis syndrome.

3. AGE DISTRIBUTION

Infants

Infection is less common during early infancy, partly because of maternal antibodies and patterns of exposure.

Toddlers and Preschool Children

Primary infection may cause:

  • Mild fever.
  • Upper respiratory symptoms.
  • Cervical lymphadenopathy.
  • Nonspecific illness.

School-Age Children

Symptoms may resemble other viral infections.

Adolescents

Classic infectious mononucleosis becomes increasingly common.

Young Adults

Often develop a recognizable syndrome of fever, pharyngitis, lymphadenopathy, and prolonged fatigue.

Clinical Importance

A young child with acute EBV infection may not have the classic findings expected in adolescent infectious mononucleosis.

4. MODES OF TRANSMISSION

Saliva

The principal route of EBV transmission.

Common Exposures

These include:

  • Kissing.
  • Sharing drinking containers.
  • Sharing utensils.
  • Contact with saliva-contaminated objects.

Blood Products

Transmission through transfusion is possible but less common.

Organ Transplantation

EBV may be transmitted through transplanted organs.

Other Body Fluids

Transmission through sexual contact and other body-fluid exposures can occur.

Vertical Transmission

Transmission around pregnancy or childbirth is uncommon and is not a major route of typical EBV acquisition.

Clinical Importance

Casual contact generally presents less risk than direct saliva exposure, and routine isolation of otherwise healthy children is unnecessary.

5. INCUBATION PERIOD

General Principles

The incubation period varies with age and the clinical syndrome.

Classic Infectious Mononucleosis

Symptoms typically develop approximately:

Four to six weeks after exposure.

Range

An incubation period of roughly four to seven weeks is often described.

Young Children

The timing of infection may be difficult to establish because symptoms are frequently mild or absent.

Clinical Importance

An exposure history may be unrevealing because infection commonly occurs weeks before symptoms develop.

6. VIRAL SHEDDING

General Principles

EBV is shed intermittently in saliva.

During Primary Infection

Salivary shedding may be substantial.

After Recovery

Viral shedding can continue for months after acute illness.

Lifelong Persistence

Previously infected individuals may intermittently shed EBV despite feeling well.

Transmission Implications

There is no reliable symptom-based point at which an individual can be considered permanently noninfectious.

Clinical Importance

Routine prolonged isolation or exclusion from school until salivary EBV shedding stops is neither practical nor recommended.

7. VIROLOGY

Virus Classification

EBV belongs to the human gammaherpesviruses.

Genetic Material

The viral genome consists of double-stranded DNA.

Viral Envelope

The envelope contains glycoproteins involved in host-cell attachment and entry.

Primary Cellular Targets

These include:

  • B lymphocytes.
  • Certain epithelial cells.

Viral Persistence

EBV establishes lifelong latency within the B-cell compartment.

Reactivation

Latent virus may periodically reactivate.

Clinical Importance

Lifelong EBV persistence is typical after infection and does not by itself indicate chronic active EBV disease.

8. PATHOPHYSIOLOGY

Initial Infection

EBV enters through exposure to infected saliva.

Oropharyngeal Involvement

The virus infects cells in the oropharyngeal region and establishes infection in B lymphocytes.

B-Cell Activation

Infected B cells undergo activation and proliferation.

Cytotoxic T-Cell Response

The immune system mounts a strong cellular response against infected cells.

Lymphoid Enlargement

Immune activation produces enlargement of:

  • Tonsils.
  • Lymph nodes.
  • Spleen.

Systemic Symptoms

The inflammatory response contributes to:

  • Fever.
  • Fatigue.
  • Malaise.
  • Myalgia.

Clinical Importance

Many manifestations of infectious mononucleosis result from the host immune response rather than direct destruction of tissues by the virus.

9. B-LYMPHOCYTE INFECTION

General Principles

EBV infects B lymphocytes through viral attachment and entry mechanisms involving cellular receptors.

CD21

CD21 is an important receptor involved in B-cell entry.

B-Cell Activation

Infection can promote proliferation and altered immune signaling.

Latency

The virus persists within a population of memory B cells.

Immune Surveillance

T-cell-mediated immunity normally controls EBV-infected B cells.

Immunodeficiency

Impaired cellular immune control may allow abnormal proliferation of infected lymphocytes.

Clinical Importance

This interaction between EBV and B-cell immunity helps explain the increased risk of lymphoproliferative complications in immunocompromised patients.

10. CELLULAR IMMUNE RESPONSE

General Principles

Cellular immunity is central to controlling primary EBV infection.

Cytotoxic T Lymphocytes

CD8-positive T lymphocytes expand in response to infected B cells.

Atypical Lymphocytes

Many atypical lymphocytes seen on peripheral blood smears are activated reactive T cells.

Cytokine Production

Inflammatory cytokines contribute to:

  • Fever.
  • Fatigue.
  • Lymph node swelling.
  • Generalized malaise.

Immune Control

Effective T-cell responses limit uncontrolled B-cell proliferation.

Clinical Importance

Atypical lymphocytosis reflects immune activation and is not equivalent to circulating malignant lymphocytes.

11. LATENCY AND REACTIVATION

General Principles

Following primary infection, EBV remains latent throughout life.

Site of Latency

Memory B lymphocytes are an important reservoir.

Reactivation

Viral replication may recur intermittently.

Immunocompetent Individuals

Reactivation is commonly asymptomatic.

Immunocompromised Individuals

Reactivation or uncontrolled EBV-associated lymphoproliferation may have greater clinical consequences.

Interpretation of Tests

Detection of EBV DNA or antibodies does not automatically indicate symptomatic active disease.

Clinical Importance

Positive EBV IgG or low-level EBV DNA detection should not be interpreted as proof that EBV is causing a child’s current symptoms.

12. CLINICAL SPECTRUM

Asymptomatic Infection

Common during childhood.

Mild Viral Illness

May cause fever, upper respiratory symptoms, or nonspecific fatigue.

Infectious Mononucleosis

Characterized by the classic systemic and lymphoid manifestations.

Organ-Specific Disease

May include:

  • Hepatitis.
  • Hemolytic anemia.
  • Neurological disease.
  • Myocarditis.

Severe Immune Dysregulation

Rarely produces:

  • Hemophagocytic lymphohistiocytosis.
  • Chronic active EBV disease.
  • Severe lymphoproliferative disorders.

Clinical Importance

Clinical severity ranges from minimal symptoms to rare life-threatening complications.

13. INFECTIOUS MONONUCLEOSIS

Description

Infectious mononucleosis is the symptomatic clinical syndrome most frequently associated with primary EBV infection in adolescents and young adults.

Classic Triad

Includes:

  1. Fever.
  2. Pharyngitis.
  3. Cervical lymphadenopathy.

Additional Features

Common findings include:

  • Fatigue.
  • Malaise.
  • Tonsillar enlargement.
  • Atypical lymphocytosis.
  • Splenomegaly.
  • Mild hepatitis.

Clinical Importance

The classic triad is helpful but is not required in every patient.

14. PRODROMAL PHASE

General Principles

A nonspecific prodrome may precede classic symptoms.

Duration

Often several days.

Symptoms

These may include:

  • Fatigue.
  • Malaise.
  • Anorexia.
  • Headache.
  • Myalgia.
  • Low-grade fever.

Adolescents

Fatigue may be particularly prominent.

Young Children

The prodrome may not be recognized.

Clinical Importance

Early EBV infection may resemble many other common viral illnesses.

15. ACUTE SYMPTOMATIC PHASE

Fever

May persist for one to two weeks.

Pharyngitis

Often becomes prominent during the acute illness.

Lymphadenopathy

Cervical lymph nodes enlarge.

Fatigue

May significantly limit school attendance and activity.

Appetite

Reduced appetite is common.

Rash

May occur with or without medication exposure.

Abdominal Symptoms

Some patients have:

  • Abdominal discomfort.
  • Nausea.
  • Reduced intake.

Clinical Importance

The duration and intensity of symptoms vary widely between children.

16. FATIGUE

General Principles

Fatigue is one of the most characteristic and sometimes prolonged manifestations.

Acute Illness

May be severe enough to interfere with daily activities.

Convalescence

Fatigue may continue after fever and pharyngitis resolve.

Duration

Many patients recover within several weeks, although fatigue may persist for months in a minority.

Evaluation

Persistent or progressive fatigue warrants assessment for:

  • Anemia.
  • Sleep problems.
  • Other infections.
  • Psychological difficulties.
  • Alternative medical conditions.

Clinical Importance

Persistent fatigue alone does not establish ongoing active EBV replication.

17. FEVER

General Principles

Fever commonly accompanies symptomatic EBV infection.

Temperature

May range from low-grade to high fever.

Duration

Frequently persists for several days to two weeks.

Associated Symptoms

These include:

  • Sweating.
  • Chills.
  • Myalgia.
  • General malaise.

Persistent Fever

Fever that persists unusually long or recurs with clinical deterioration requires reassessment.

Clinical Importance

Persistent or recurrent fever may indicate a complication, secondary infection, or alternative diagnosis.

18. TONSILLOPHARYNGITIS

General Principles

EBV may produce marked tonsillar and pharyngeal inflammation.

Typical Findings

These include:

  • Enlarged tonsils.
  • Pharyngeal erythema.
  • Tonsillar exudates.
  • Painful swallowing.

Exudative Disease

May closely resemble group A streptococcal pharyngitis.

Severe Enlargement

Can cause:

  • Dysphagia.
  • Drooling.
  • Muffled voice.
  • Upper airway obstruction.

Clinical Importance

Exudative tonsillitis does not establish bacterial infection; EBV and streptococcal pharyngitis may appear similar.

19. PALATAL PETECHIAE

Description

Small red or purple hemorrhagic spots may appear on the soft palate.

Associated Conditions

Palatal petechiae can occur with:

  • EBV infection.
  • Group A streptococcal pharyngitis.
  • Other infections.

Diagnostic Value

Supportive but nonspecific.

Clinical Importance

Palatal petechiae should be interpreted alongside the overall syndrome rather than used as a standalone diagnostic sign.

20. LYMPHADENOPATHY

General Principles

Lymph node enlargement is a common manifestation.

Typical Distribution

Frequently affects:

  • Posterior cervical nodes.
  • Anterior cervical nodes.
  • Other lymph node chains.

Characteristics

Nodes may be:

  • Enlarged.
  • Mobile.
  • Mildly tender.
  • Bilateral.

Generalized Adenopathy

May involve axillary or inguinal regions.

Resolution

Nodes generally decrease in size over subsequent weeks.

Clinical Importance

Posterior cervical lymphadenopathy is particularly suggestive when accompanied by fatigue and exudative pharyngitis.

21. SPLENOMEGALY

General Principles

Splenic enlargement results from lymphoid proliferation and immune activation.

Timing

May become most prominent during the first several weeks of illness.

Physical Examination

The spleen may be palpable below the left costal margin.

Important Limitation

Physical examination is not reliably sensitive for detecting splenic enlargement.

Imaging

Ultrasound may demonstrate enlargement, but normal spleen dimensions vary substantially.

Clinical Importance

Splenomegaly creates a risk of splenic rupture and is a major reason for temporary restrictions on athletic activity.

22. HEPATOMEGALY AND HEPATITIS

General Principles

Mild hepatic inflammation is common during symptomatic EBV infection.

Clinical Features

May include:

  • Mild right upper abdominal discomfort.
  • Hepatomegaly.
  • Nausea.
  • Reduced appetite.

Laboratory Findings

Transaminase elevations are frequent.

Jaundice

Clinically apparent jaundice is less common.

Severe Hepatitis

Marked liver injury or acute liver failure is rare.

Clinical Importance

EBV-associated transaminase elevation is usually self-limited, but severe or progressive abnormalities require evaluation for other causes and complications.

23. EXANTHEM AND SKIN FINDINGS

General Principles

EBV infection can produce several skin manifestations.

Maculopapular Rash

May occur spontaneously.

Aminopenicillin-Associated Rash

A diffuse morbilliform eruption may develop after amoxicillin or ampicillin exposure.

Other Findings

Occasional manifestations include:

  • Urticarial eruption.
  • Petechiae.
  • Other nonspecific rashes.

Important Distinction

A rash during EBV infection does not automatically indicate an IgE-mediated penicillin allergy.

Clinical Importance

Medication-associated rashes should be documented carefully, with later allergy assessment when appropriate.

24. PRESENTATION IN YOUNG CHILDREN

General Principles

Primary EBV infection in younger children is frequently mild or asymptomatic.

Potential Symptoms

These include:

  • Fever.
  • Coryza.
  • Pharyngitis.
  • Lymphadenopathy.
  • Rash.
  • Abdominal pain.

Atypical Features

The classic adolescent syndrome may be absent.

Laboratory Interpretation

Heterophile tests are less sensitive in young children.

Clinical Importance

EBV-specific serology is preferred over a heterophile assay when laboratory confirmation is necessary in young children.

25. PRESENTATION IN ADOLESCENTS

General Principles

Adolescents are more likely to experience classic infectious mononucleosis.

Prominent Symptoms

These include:

  • Severe fatigue.
  • Fever.
  • Sore throat.
  • Swollen cervical lymph nodes.
  • Reduced physical activity tolerance.

School Impact

Illness may interfere with attendance and academic work.

Sports Participation

Athletic restrictions may be necessary because of splenic rupture risk.

Clinical Importance

Counseling should address both symptom recovery and safe return to physical activity.

26. HISTORY

General Principles

History should establish illness duration, typical manifestations, and warning signs.

Symptom Timeline

Ask about:

  • Initial fatigue.
  • Fever onset.
  • Sore throat progression.
  • Duration of lymph node swelling.

Oral Intake

Assess drinking and swallowing.

Breathing

Ask about:

  • Snoring.
  • Noisy breathing.
  • Dyspnea.
  • Inability to swallow secretions.

Abdominal Pain

Ask specifically about left upper quadrant pain.

Medications

Review antibiotics, particularly aminopenicillins.

Clinical Importance

A focused history helps identify patients needing urgent airway or abdominal assessment.

27. EXPOSURE HISTORY

Saliva Exposure

Ask about relevant close contacts when appropriate.

Household Illness

Other family members may have symptoms.

School and Social Exposure

Transmission may occur in settings involving close contact.

Travel

Usually not necessary to establish typical EBV infection but may inform the differential diagnosis.

Transplantation

Organ transplant history significantly changes the risk assessment.

Immunosuppression

Ask about:

  • Chemotherapy.
  • Transplant medications.
  • Primary immunodeficiency.
  • Other immunosuppressive treatment.

Clinical Importance

A recognizable exposure is often absent and is not required to diagnose EBV infection.

28. PHYSICAL EXAMINATION

General Appearance

Assess:

  • Hydration.
  • Alertness.
  • Fatigue.
  • Respiratory effort.

Oropharynx

Inspect for:

  • Tonsillar enlargement.
  • Exudates.
  • Palatal petechiae.
  • Uvular position.

Neck

Assess cervical lymphadenopathy.

Abdomen

Evaluate for:

  • Hepatomegaly.
  • Splenomegaly.
  • Tenderness.

Skin

Look for rash, petechiae, or jaundice.

Neurological Examination

Indicated when neurological symptoms are present.

Clinical Importance

The examination should identify complications rather than merely confirm the classic pharyngitis syndrome.

29. RED FLAGS

Respiratory Distress

May indicate severe tonsillar or pharyngeal obstruction.

Drooling or Inability to Swallow

May indicate severe airway or swallowing compromise.

Severe Left Upper Quadrant Pain

Raises concern for splenic injury.

Referred Left Shoulder Pain

May occur with diaphragmatic irritation from intra-abdominal bleeding.

Syncope or Hypotension

May indicate hemorrhage or another serious complication.

Confusion or Seizures

May indicate neurological involvement.

Marked Pallor or Jaundice

May indicate hemolytic anemia.

Persistent High Fever With Deterioration

May indicate a secondary infection or severe inflammatory complication.

Clinical Importance

Sudden left upper abdominal pain, collapse, or respiratory distress in a child with infectious mononucleosis requires emergency evaluation.

30. DIFFERENTIAL DIAGNOSIS

Infectious Causes

Consider:

  • Group A streptococcal pharyngitis.
  • Cytomegalovirus.
  • Adenovirus.
  • Acute HIV infection.
  • Toxoplasmosis.
  • Human herpesvirus 6.
  • Influenza.
  • Other respiratory viral infections.

Bacterial Conditions

Consider:

  • Peritonsillar abscess.
  • Retropharyngeal abscess.
  • Diphtheria in relevant circumstances.

Hematological Disorders

Consider:

  • Leukemia.
  • Lymphoma.

Systemic Inflammatory Conditions

Selected autoimmune and inflammatory diseases may mimic some features.

Clinical Importance

The combination of fever, lymphadenopathy, and atypical lymphocytes is suggestive but not unique to EBV infection.

31. GROUP A STREPTOCOCCAL PHARYNGITIS

General Principles

Streptococcal tonsillopharyngitis may resemble EBV infection.

Shared Features

These include:

  • Fever.
  • Sore throat.
  • Tonsillar exudate.
  • Cervical lymphadenopathy.

Findings Suggesting EBV

These include:

  • Prominent fatigue.
  • Posterior cervical adenopathy.
  • Splenomegaly.
  • Generalized lymphadenopathy.

Testing

Rapid antigen testing or throat culture may be indicated when streptococcal infection is clinically plausible.

Coinfection and Carriage

Positive streptococcal testing can occasionally reflect carriage rather than causative infection.

Clinical Importance

Treat confirmed clinically relevant group A streptococcal infection appropriately, but avoid empirical aminopenicillins when EBV is strongly suspected and bacterial infection has not been established.

32. CYTOMEGALOVIRUS MONONUCLEOSIS

General Principles

Cytomegalovirus can produce a heterophile-negative mononucleosis-like syndrome.

Features

Possible findings include:

  • Prolonged fever.
  • Fatigue.
  • Malaise.
  • Atypical lymphocytosis.
  • Elevated liver enzymes.

Pharyngitis

May be less prominent than in classic EBV mononucleosis.

Diagnosis

CMV-specific serology or molecular testing may be indicated in selected cases.

Clinical Importance

CMV should be considered when the mononucleosis syndrome is convincing but EBV testing does not support recent infection.

33. ACUTE HIV INFECTION

General Principles

Acute HIV infection may resemble infectious mononucleosis.

Potential Features

These include:

  • Fever.
  • Sore throat.
  • Lymphadenopathy.
  • Rash.
  • Fatigue.
  • Mucosal ulcers.

Risk Assessment

Use a confidential, age-appropriate exposure history.

Testing

Appropriate HIV antigen-antibody and nucleic acid testing may be necessary depending on the timing of exposure.

Clinical Importance

Acute HIV should be considered in an adolescent with compatible symptoms and relevant risk, especially when EBV studies are negative.

34. HEMATOLOGICAL MALIGNANCY

General Principles

Leukemia and lymphoma may present with fever, fatigue, and lymphadenopathy.

Concerning Findings

These include:

  • Persistent or progressive adenopathy.
  • Unexplained bruising.
  • Significant cytopenias.
  • Bone pain.
  • Weight loss.
  • Persistent night sweats.
  • Unusual organ enlargement.

Laboratory Findings

CBC and blood smear abnormalities may raise suspicion.

Clinical Importance

A prolonged or atypical illness should not automatically be attributed to EBV without reassessing for alternative diagnoses.

35. INITIAL DIAGNOSTIC APPROACH

General Principles

Typical infectious mononucleosis may be diagnosed clinically.

When Testing Is Useful

Consider laboratory confirmation when:

  • The diagnosis is uncertain.
  • Symptoms are atypical.
  • Important alternatives must be excluded.
  • Sports participation decisions require clarification.
  • Complications are suspected.
  • The patient is immunocompromised.

Initial Tests

May include:

  • CBC with differential.
  • Liver enzymes.
  • EBV-specific serology.

Heterophile Testing

May be useful in some adolescents but has important limitations.

Clinical Importance

Laboratory investigations should answer a specific clinical question rather than be ordered routinely for every mild viral illness.

36. COMPLETE BLOOD COUNT

General Principles

CBC abnormalities may support a diagnosis of infectious mononucleosis.

Leukocyte Count

May be normal or elevated.

Lymphocytosis

An increased lymphocyte proportion is common.

Atypical Lymphocytes

Reactive lymphocytes may constitute more than 10% of leukocytes.

Neutropenia

Mild transient neutropenia can occur.

Thrombocytopenia

Mild platelet reduction may be present.

Anemia

Severe anemia is unusual and requires evaluation for hemolysis or another process.

Clinical Importance

Atypical lymphocytosis is supportive but not specific for EBV.

37. ATYPICAL LYMPHOCYTES

Description

Atypical or reactive lymphocytes are activated immune cells with characteristic blood smear appearances.

Morphology

They may demonstrate:

  • Enlarged cell size.
  • Abundant cytoplasm.
  • Irregular cell contours.
  • Reactive nuclear changes.

Clinical Context

Commonly associated with EBV but may occur with:

  • CMV.
  • Toxoplasmosis.
  • Other infections.

Important Distinction

Reactive lymphocytes are not equivalent to leukemic blasts.

Clinical Importance

Atypical smear findings that are unusual or accompanied by significant cytopenias may warrant hematopathology review.

38. HETEROPHILE ANTIBODY TESTING

General Principles

The heterophile antibody test, often called the Monospot test, detects nonspecific antibodies associated with infectious mononucleosis.

Potential Use

May support diagnosis in adolescents with a typical presentation.

Limitations

False-negative results are more common:

  • Early in illness.
  • In children younger than five years.

False Positives

May occur with certain other conditions.

Persistence

Heterophile antibodies can remain detectable after recovery.

Current Diagnostic Preference

EBV-specific serology provides more reliable evidence of the stage of EBV infection.

Clinical Importance

A negative Monospot test does not rule out acute EBV infection, particularly in young children or during the first week of symptoms.

39. EBV-SPECIFIC SEROLOGY

General Principles

EBV serology helps distinguish:

  • Susceptibility.
  • Primary infection.
  • Past infection.
  • Selected indeterminate patterns.

Main Markers

These include:

  • Viral capsid antigen IgM.
  • Viral capsid antigen IgG.
  • EBV nuclear antigen IgG.

Additional Markers

Early antigen antibodies may occasionally contribute information.

Interpretation

The combination of markers is more useful than any single result.

Clinical Importance

EBV-specific antibody patterns are generally preferred over heterophile testing when laboratory confirmation is important in pediatric patients.

40. VCA IgM

Description

IgM antibodies against the EBV viral capsid antigen appear early during primary infection.

Timing

Often become detectable near symptom onset.

Duration

Usually disappear within approximately four to six weeks, although variation occurs.

Interpretation

Positive VCA IgM with absent EBNA IgG supports primary EBV infection.

Limitations

False positivity and atypical patterns can occur.

Clinical Importance

VCA IgM should be interpreted together with VCA IgG, EBNA IgG, and the clinical presentation.

41. VCA IgG

Description

Viral capsid antigen IgG antibodies develop during primary infection.

Timing

Usually appear early in the acute illness.

Persistence

Generally remain detectable for life.

Interpretation

VCA IgG alone does not establish current infection.

Past Infection

VCA IgG positivity together with EBNA IgG commonly indicates previous infection.

Clinical Importance

A positive EBV VCA IgG result is not evidence that EBV is responsible for a child’s current illness.

42. EBNA IgG

Description

EBV nuclear antigen IgG develops later after primary infection.

Timing

Typically appears approximately two to four months after symptom onset, depending on the assay.

Persistence

Usually remains positive throughout life.

Acute Infection

EBNA IgG is generally absent during early primary infection.

Past Infection

Positive EBNA IgG with VCA IgG supports remote infection.

Important Limitation

Certain assays may produce atypical or false-positive results.

Clinical Importance

EBNA IgG helps distinguish recent primary infection from previous EBV exposure.

43. SEROLOGICAL PATTERNS

Susceptible Individual

Typical findings:

  • VCA IgM negative.
  • VCA IgG negative.
  • EBNA IgG negative.

Acute Primary Infection

Typical findings:

  • VCA IgM positive.
  • VCA IgG positive or becoming positive.
  • EBNA IgG negative.

Past Infection

Typical findings:

  • VCA IgM negative.
  • VCA IgG positive.
  • EBNA IgG positive.

Indeterminate Patterns

May occur with:

  • Early seroconversion.
  • Assay variability.
  • Persistent IgM.
  • Cross-reactive antibodies.

Clinical Importance

Unusual patterns may require repeat or confirmatory testing, but repeated testing is unnecessary when the clinical diagnosis is already clear.

44. EARLY ANTIGEN ANTIBODIES

General Principles

Antibodies against EBV early antigens may develop during active infection.

EA IgG

May appear during the acute phase.

Persistence

Can remain detectable for years in some healthy individuals.

Interpretation

EA IgG positivity alone does not prove active symptomatic EBV disease.

Clinical Role

Usually unnecessary for routine diagnosis of uncomplicated infectious mononucleosis.

Clinical Importance

Early antigen results should not be used in isolation to diagnose chronic EBV-related illness.

45. EBV PCR

General Principles

Molecular testing detects EBV DNA in blood or other specimens.

Routine Mononucleosis

PCR is not usually necessary to confirm uncomplicated primary infection.

Important Uses

Include:

  • Immunocompromised patients.
  • Transplant recipients.
  • Suspected posttransplant lymphoproliferative disorder.
  • Selected severe or atypical disease.

Interpretation

A positive PCR may reflect:

  • Active viral replication.
  • EBV-infected circulating cells.
  • Other EBV-associated processes.

Viral Load

Serial quantitative testing may be useful in selected immunocompromised patients.

Clinical Importance

A detectable EBV viral load does not by itself establish EBV as the cause of fever, fatigue, or another nonspecific symptom.

46. LIVER FUNCTION TESTS

General Principles

Mild hepatitis commonly accompanies symptomatic EBV infection.

Typical Findings

These include elevated:

  • Alanine aminotransferase.
  • Aspartate aminotransferase.

Additional Abnormalities

Occasionally:

  • Elevated bilirubin.
  • Increased alkaline phosphatase.
  • Elevated gamma-glutamyl transferase.

Severe Disease

Marked enzyme elevation, impaired coagulation, or jaundice warrants additional evaluation.

Clinical Importance

Routine serial liver testing is not necessary in every mild case, but significant abnormalities should be followed until improvement.

47. HEMATOLOGICAL INVESTIGATIONS

General Principles

Additional testing is indicated when clinically important cytopenias or hemolysis are suspected.

Hemolysis Evaluation

May include:

  • Hemoglobin.
  • Reticulocyte count.
  • Bilirubin.
  • Lactate dehydrogenase.
  • Haptoglobin.
  • Direct antiglobulin test.

Severe Thrombocytopenia

Evaluate platelet count and bleeding risk.

Neutropenia

Assess severity and infection risk.

HLH Evaluation

Consider ferritin, triglycerides, fibrinogen, and other specialized investigations when the clinical presentation is concerning.

Clinical Importance

Severe cytopenias are not typical uncomplicated mononucleosis and require prompt assessment.

48. ABDOMINAL ULTRASOUND

General Principles

Ultrasound can evaluate splenic size and certain abdominal complications.

Potential Indications

These include:

  • Suspected splenic injury.
  • Unexplained abdominal symptoms.
  • Selected uncertain examinations.

Limitations

Normal spleen dimensions vary with:

  • Age.
  • Height.
  • Body habitus.
  • Individual baseline size.

Return to Sports

Routine ultrasound is not recommended solely to determine whether an otherwise recovering athlete may return to activity.

Clinical Importance

Ultrasound findings should not replace clinical recovery and an individualized return-to-sport assessment.

49. TREATMENT PRINCIPLES

General Principles

Treatment of uncomplicated infectious mononucleosis is supportive.

Main Objectives

These include:

  1. Maintain hydration.
  2. Relieve pain and fever.
  3. Support adequate nutrition.
  4. Allow symptom-guided rest.
  5. Identify complications.
  6. Reduce splenic injury risk.

Antiviral Medication

Not routinely recommended.

Antibiotics

Not indicated unless a separate bacterial infection is present.

Corticosteroids

Not routinely indicated.

Clinical Importance

Most immunocompetent children recover without disease-specific pharmacological treatment.

50. HYDRATION

General Principles

Adequate fluid intake is important, especially with painful swallowing.

Oral Hydration

Encourage frequent small drinks.

Suitable Fluids

These may include:

  • Water.
  • Oral rehydration solution.
  • Other tolerated beverages.

Soft Foods

May be easier to swallow.

Dehydration Signs

These include:

  • Reduced urination.
  • Dry mouth.
  • Dizziness.
  • Lethargy.
  • Poor tear production.

Intravenous Fluids

May be needed when oral intake is inadequate.

Clinical Importance

Dehydration from severe pharyngitis is an important potentially preventable reason for hospitalization.

51. ACETAMINOPHEN

General Principles

Acetaminophen may reduce fever and throat pain.

Pediatric Dose

10–15 mg/kg per dose orally every four to six hours as needed.

Maximum Dose

Follow local pediatric maximum daily dosing and avoid duplicate acetaminophen-containing products.

Liver Precautions

Use particular caution with:

  • Significant hepatitis.
  • Liver dysfunction.
  • Dehydration.
  • Other hepatotoxic medication exposure.

Clinical Importance

Appropriate symptom relief can improve oral intake, but excessive acetaminophen dosing should be avoided.

52. IBUPROFEN

General Principles

Ibuprofen may reduce fever and throat discomfort.

Pediatric Dose

For eligible children aged six months or older:

5–10 mg/kg per dose orally every six to eight hours as needed.

Typical Maximum

Do not exceed the age- and weight-appropriate daily maximum, commonly 40 mg/kg/day.

Contraindications and Precautions

Avoid or use caution with:

  • Significant dehydration.
  • Acute kidney injury.
  • Gastrointestinal bleeding.
  • NSAID hypersensitivity.

Thrombocytopenia

Avoid NSAIDs when clinically important bleeding risk is present.

Clinical Importance

Analgesics should be chosen according to the child’s hydration, kidney function, liver status, and bleeding risk.

53. REST AND ACTIVITY

General Principles

Rest is appropriate during the symptomatic phase.

Sleep

Encourage adequate sleep.

Daily Activities

Resume light activities as tolerated once systemic symptoms improve.

Prolonged Bed Rest

Strict bed rest is not necessary throughout recovery.

Athletic Activity

Requires separate consideration because of splenic rupture risk.

Fatigue

Activity should be increased gradually rather than abruptly.

Clinical Importance

Symptom-guided recovery is appropriate for normal daily activities, but vigorous exercise and contact sports require additional restrictions.

54. SORE THROAT MANAGEMENT

Supportive Measures

These may include:

  • Oral fluids.
  • Cold beverages.
  • Soft foods.
  • Age-appropriate analgesics.
  • Salt-water gargles in children old enough to perform them safely.

Severe Symptoms

Assess for:

  • Dehydration.
  • Airway obstruction.
  • Peritonsillar abscess.
  • Secondary bacterial infection.

Avoid

Do not use antibiotics solely because the tonsils have exudates.

Clinical Importance

The ability to maintain oral intake is an important measure of illness severity.

55. ANTIBIOTIC USE

General Principles

Antibiotics do not treat EBV infection.

Indications

Use only when a separate bacterial infection is established or strongly suspected.

Group A Streptococcus

Treat according to appropriate testing and local guidelines.

Aminopenicillins

Amoxicillin and ampicillin are associated with an increased frequency of rash during acute EBV infection.

Important Distinction

An aminopenicillin-associated rash does not invariably indicate a persistent penicillin allergy.

Clinical Importance

Avoid unnecessary antibiotics in EBV mononucleosis, particularly when exudative pharyngitis has not been confirmed as bacterial.

56. AMINOPENICILLIN-ASSOCIATED RASH

General Principles

A morbilliform rash may occur during EBV infection after aminopenicillin exposure.

Clinical Appearance

Often characterized by:

  • Diffuse pink or red macules.
  • Papules.
  • Symmetric distribution.
  • Variable itching.

Timing

Frequently develops several days after the antibiotic is started.

Mechanism

May involve transient immune alterations, although true drug hypersensitivity can also coexist.

Management

Reassess whether the antibiotic is necessary.

Allergy Assessment

Consider formal evaluation if the history suggests immediate hypersensitivity or the future penicillin allergy label is uncertain.

Clinical Importance

Do not permanently label every child with an EBV-associated amoxicillin rash as penicillin-allergic without reviewing the reaction.

57. CORTICOSTEROIDS

General Principles

Systemic corticosteroids are not recommended for routine uncomplicated infectious mononucleosis.

Potential Indications

May be considered for serious complications such as:

  • Impending upper airway obstruction.
  • Severe immune-mediated hemolytic anemia.
  • Severe immune thrombocytopenia.
  • Selected life-threatening inflammatory complications.

Treatment Selection

Depends on:

  • Severity.
  • Clinical condition.
  • Organ involvement.
  • Specialist assessment.

Dosing

There is no single standard corticosteroid regimen appropriate for all EBV complications.

Important Limitation

Routine corticosteroids do not reliably shorten uncomplicated illness or prevent prolonged fatigue.

Clinical Importance

Corticosteroids should be reserved for selected serious complications, not prescribed merely for severe-looking tonsillar exudates or routine sore throat.

58. ANTIVIRAL THERAPY

General Principles

Acyclovir and related antivirals inhibit aspects of lytic EBV replication.

Clinical Evidence

They may reduce viral shedding but have not shown consistent meaningful improvement in uncomplicated infectious mononucleosis outcomes.

Routine Use

Not recommended.

Severe EBV Disease

Specialist-directed antiviral treatment may occasionally be considered in unusual circumstances.

Transplant Recipients

Management is different and focuses on immune control and EBV-associated complications.

Clinical Importance

Routine acyclovir or valacyclovir should not be prescribed for uncomplicated EBV mononucleosis.

59. AIRWAY OBSTRUCTION

General Principles

Marked tonsillar and adenoidal enlargement may narrow the upper airway.

Symptoms

These include:

  • Difficulty breathing.
  • Noisy breathing.
  • Severe snoring.
  • Drooling.
  • Inability to swallow.
  • Muffled voice.

Initial Management

Requires urgent airway assessment.

Treatment

May include:

  • Hospital admission.
  • ENT consultation.
  • Carefully selected systemic corticosteroids.
  • Airway support.

Severe Cases

Intubation may rarely be required.

Clinical Importance

Progressive respiratory difficulty in EBV mononucleosis is an emergency and should not be managed solely with outpatient steroids.

60. SPLENIC RUPTURE

General Principles

Splenic rupture is an uncommon but potentially fatal complication.

Mechanism

Splenic enlargement and altered tissue integrity increase susceptibility to injury.

Traumatic Rupture

May occur after abdominal impact or athletic activity.

Atraumatic Rupture

Can occur without a recognized injury.

Symptoms

These include:

  • Sudden left upper quadrant pain.
  • Left shoulder pain.
  • Dizziness.
  • Syncope.
  • Pallor.
  • Hypotension.

Emergency Management

Requires immediate hospital evaluation and resuscitation.

Clinical Importance

Sudden abdominal pain or collapse during or after infectious mononucleosis must raise concern for splenic rupture, even without a history of trauma.

61. RETURN TO SPORTS

General Principles

Physical activity restrictions aim to reduce the risk of splenic injury.

Initial Restriction

Current sports medicine guidance commonly recommends avoiding athletic activity for at least:

Three weeks from symptom onset.

Early Return

After approximately three weeks, gradual light noncontact activity may be considered if the athlete is:

  • Afebrile.
  • Clinically well.
  • Recovering appropriately.
  • Free of concerning abdominal symptoms.

Contact Sports

Require additional individualized assessment because of potential abdominal trauma.

Heavy Lifting

Should also be considered in activity restrictions.

Clinical Importance

A blanket clearance at exactly 21 days is inappropriate for children who remain symptomatic or participate in activities with substantial abdominal impact risk.

62. SPORTS CLEARANCE AND SPLENIC IMAGING

General Principles

Return-to-play decisions should consider the child’s clinical recovery and sport.

Clinical Factors

These include:

  • Date of symptom onset.
  • Resolution of systemic illness.
  • Abdominal symptoms.
  • Sport-specific injury risk.
  • Individual circumstances.

Physical Examination

Cannot reliably determine whether the spleen has returned to normal size.

Ultrasound

Routine single-point ultrasound is not recommended solely to accelerate clearance.

Contact Sports

Shared decision-making is necessary and may involve a longer restriction period.

Clinical Importance

No single ultrasound measurement reliably establishes that splenic rupture risk has returned to zero.

63. HEMOLYTIC ANEMIA

General Principles

EBV may trigger autoimmune hemolytic anemia.

Mechanisms

Cold-reactive antibodies are associated with some cases.

Clinical Features

These include:

  • Pallor.
  • Fatigue.
  • Jaundice.
  • Dark urine.
  • Tachycardia.

Investigations

May include:

  • CBC.
  • Reticulocyte count.
  • Bilirubin.
  • LDH.
  • Haptoglobin.
  • Direct antiglobulin test.

Treatment

Depends on severity and mechanism.

Clinical Importance

Severe anemia, rapidly progressive jaundice, or hemodynamic instability requires urgent assessment.

64. THROMBOCYTOPENIA

General Principles

Mild thrombocytopenia is relatively common during acute EBV infection.

Severe Disease

Marked platelet reduction is much less common.

Clinical Features

Possible findings include:

  • Petechiae.
  • Bruising.
  • Epistaxis.
  • Mucosal bleeding.

Investigations

CBC and blood smear are central.

Treatment

Mild cases often require observation.

Severe immune-mediated thrombocytopenia may require specialist-directed treatment.

Clinical Importance

Significant bleeding or very low platelet counts require prompt hematology involvement.

65. NEUTROPENIA AND BONE MARROW SUPPRESSION

General Principles

Transient neutropenia may occur during EBV infection.

Severity

Most cases are mild.

Severe Neutropenia

May increase susceptibility to bacterial infection.

Rare Complications

EBV has been associated with severe marrow suppression and aplastic anemia.

Assessment

Investigate persistent or severe cytopenias.

Clinical Importance

Prolonged pancytopenia should not be attributed automatically to uncomplicated EBV infection.

66. EBV-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Description

Hemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening syndrome of excessive immune activation.

EBV Association

EBV is an important infectious trigger of secondary HLH.

Clinical Features

These may include:

  • Persistent high fever.
  • Hepatosplenomegaly.
  • Cytopenias.
  • Liver dysfunction.
  • Coagulopathy.
  • Neurological symptoms.

Laboratory Clues

May include:

  • Very high ferritin.
  • Elevated triglycerides.
  • Low fibrinogen.
  • Cytopenias.

Management

Requires urgent specialist treatment and may include immune-directed therapy.

Clinical Importance

Persistent fever with worsening cytopenias, hepatosplenomegaly, and organ dysfunction should prompt urgent evaluation for HLH.

67. NEUROLOGICAL COMPLICATIONS

General Principles

Neurological complications are uncommon but may be serious.

Potential Syndromes

These include:

  • Aseptic meningitis.
  • Encephalitis.
  • Cerebellitis.
  • Guillain-Barré syndrome.
  • Facial nerve palsy.
  • Transverse myelitis.
  • Optic neuritis.

Clinical Features

May include:

  • Severe headache.
  • Altered consciousness.
  • Seizures.
  • Ataxia.
  • Weakness.
  • Cranial nerve abnormalities.

Evaluation

May require:

  • Neuroimaging.
  • Lumbar puncture.
  • EEG.
  • Specialist laboratory testing.

Clinical Importance

Neurological symptoms should be investigated independently rather than assumed to be benign manifestations of mononucleosis.

68. HEPATIC COMPLICATIONS

General Principles

Most EBV-associated hepatitis is mild and self-limited.

Typical Findings

Include moderate transaminase elevation.

Cholestatic Hepatitis

May cause:

  • Jaundice.
  • Dark urine.
  • Pale stools.
  • Pruritus.

Severe Hepatitis

Rarely causes significant synthetic dysfunction.

Acute Liver Failure

Very uncommon but life-threatening.

Monitoring

Assess coagulation and liver function when significant hepatic injury is suspected.

Clinical Importance

Jaundice, encephalopathy, abnormal coagulation, or rapidly rising liver enzymes require urgent specialist assessment.

69. CARDIAC COMPLICATIONS

General Principles

Cardiac involvement is rare.

Myocarditis

May cause:

  • Chest pain.
  • Tachycardia.
  • Dyspnea.
  • Reduced cardiac function.

Pericarditis

May present with chest pain and pericardial inflammation.

Arrhythmias

Can occur with myocardial involvement.

Investigations

May include:

  • ECG.
  • Troponin.
  • Echocardiography.
  • Cardiac MRI in selected cases.

Clinical Importance

Chest pain, syncope, unexplained tachycardia, or signs of heart failure require prompt assessment.

70. EBV IN IMMUNOCOMPROMISED CHILDREN

General Principles

Impaired immune surveillance increases the risk of severe or persistent EBV-associated disease.

High-Risk Groups

These include:

  • Solid organ transplant recipients.
  • Hematopoietic stem cell transplant recipients.
  • Children receiving significant immunosuppression.
  • Selected primary immunodeficiency disorders.

Potential Complications

These include:

  • High EBV viral loads.
  • Lymphoproliferative disease.
  • Severe organ involvement.
  • Uncontrolled B-cell proliferation.

Monitoring

Some patients require quantitative EBV PCR surveillance.

Clinical Importance

EBV infection in a transplant recipient requires a different diagnostic and treatment approach from uncomplicated mononucleosis in an immunocompetent child.

71. POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER

Description

Posttransplant lymphoproliferative disorder (PTLD) encompasses abnormal lymphoid proliferation developing in the setting of transplant-associated immunosuppression.

EBV Association

Many pediatric PTLD cases are EBV-associated.

Risk Factors

These include:

  • EBV-seronegative recipient status before transplant.
  • Primary EBV infection after transplantation.
  • Intensity of immunosuppression.
  • Type of transplant.

Clinical Features

May include:

  • Fever.
  • Lymphadenopathy.
  • Tonsillar enlargement.
  • Organ masses.
  • Unexplained graft dysfunction.

Diagnosis

Requires appropriate imaging and often tissue biopsy.

Clinical Importance

EBV viral load supports monitoring but does not independently diagnose PTLD.

72. PTLD TREATMENT

General Principles

Treatment is determined by transplant and oncology specialists.

Reduction of Immunosuppression

Often an important initial strategy when feasible.

Rituximab

May be appropriate for selected CD20-positive B-cell PTLD.

Chemotherapy

Required for certain aggressive or refractory forms.

Surgical Treatment

May occasionally be appropriate for localized disease or complications.

Monitoring

Includes:

  • EBV viral load trends.
  • Disease imaging.
  • Graft function.
  • Treatment toxicity.

Clinical Importance

Treatment must balance control of lymphoproliferative disease against the risk of transplanted organ rejection.

73. CHRONIC ACTIVE EBV DISEASE

Description

Chronic active EBV disease is a rare, serious EBV-associated lymphoproliferative or inflammatory disorder involving persistently infected T or NK cells in many recognized cases.

Clinical Features

May include:

  • Persistent or recurrent fever.
  • Hepatosplenomegaly.
  • Lymphadenopathy.
  • Hepatitis.
  • Cytopenias.
  • Organ dysfunction.

Diagnostic Requirements

Require more than prolonged fatigue or positive EBV antibodies.

Assessment

May involve:

  • EBV DNA quantification.
  • Identification of infected cell populations.
  • Tissue studies.
  • Specialist evaluation.

Treatment

Severe disease may require hematopoietic stem cell transplantation.

Clinical Importance

Chronic active EBV disease is distinct from prolonged fatigue after ordinary infectious mononucleosis.

74. X-LINKED LYMPHOPROLIFERATIVE DISEASE

General Principles

Certain inherited immune disorders are associated with severe EBV susceptibility.

X-Linked Lymphoproliferative Disease

May cause unusually severe reactions to EBV.

Potential Manifestations

These include:

  • HLH.
  • Severe hepatitis.
  • Lymphoma.
  • Dysgammaglobulinemia.
  • Fulminant infection.

Genetic Mechanisms

Defects in specific immune regulatory pathways may impair EBV control.

Family History

Ask about:

  • Male relatives with severe EBV disease.
  • Unexplained early deaths.
  • Familial immunodeficiency.

Clinical Importance

Severe EBV disease in a young boy may warrant assessment for an underlying primary immune disorder.

75. EBV-ASSOCIATED MALIGNANCIES

General Principles

EBV is associated with several malignancies, but the overwhelming majority of infected children never develop cancer.

Important Associations

These include:

  • Burkitt lymphoma.
  • Hodgkin lymphoma.
  • Certain non-Hodgkin lymphomas.
  • Nasopharyngeal carcinoma.
  • Posttransplant lymphoproliferative disorders.

Geographic Factors

Associations vary by region and cofactors.

Immune Status

Immunosuppression increases risk for some EBV-associated lymphoid malignancies.

Clinical Importance

Past EBV infection is extremely common and does not mean that a child will develop an EBV-associated cancer.

76. HOSPITAL ADMISSION

General Principles

Most immunocompetent children with infectious mononucleosis can be treated as outpatients.

Admission Indications

These include:

  • Upper airway obstruction.
  • Significant dehydration.
  • Inability to swallow fluids.
  • Suspected splenic rupture.
  • Severe anemia.
  • Significant thrombocytopenia with bleeding.
  • Neurological complications.
  • Severe hepatitis.
  • Suspected HLH.

Immunocompromised Patients

May require admission for specialized evaluation.

Clinical Importance

Hospitalization is driven by complications and physiological instability, not a positive EBV test alone.

77. PEDIATRIC INTENSIVE CARE

General Principles

PICU admission is necessary for selected severe complications.

Indications

These include:

  • Severe airway obstruction.
  • Respiratory failure.
  • Hemorrhagic shock.
  • Severe encephalitis.
  • Fulminant HLH.
  • Severe myocarditis.
  • Multiorgan dysfunction.

Monitoring

May include:

  • Continuous ECG.
  • Respiratory monitoring.
  • Hemodynamic monitoring.
  • Serial blood testing.

Organ Support

May require:

  • Mechanical ventilation.
  • Vasoactive medications.
  • Blood products.
  • Specialized immune-directed treatment.

Clinical Importance

Rapid escalation is essential when an ordinarily benign EBV illness develops a life-threatening complication.

78. NURSING CONSIDERATIONS

General Principles

Nursing care focuses on hydration, comfort, recognition of complications, and education.

Monitoring

Assess:

  • Temperature.
  • Oral intake.
  • Urine output.
  • Pain.
  • Respiratory status.
  • Fatigue.

Throat Symptoms

Observe for increasing tonsillar swelling or swallowing difficulty.

Abdominal Symptoms

Report sudden left upper quadrant pain.

Medication Safety

Ensure age-appropriate antipyretic dosing.

Emotional Support

Help the child and family understand the expected recovery course.

Clinical Importance

Prompt identification of worsening airway, abdominal, or neurological symptoms can prevent serious adverse outcomes.

79. INFECTION CONTROL AND SCHOOL ATTENDANCE

General Principles

Routine standard precautions are appropriate for most hospitalized patients.

Additional Precautions

May be required when another transmissible infection is suspected.

School Attendance

Children may return when they:

  • Are afebrile.
  • Feel sufficiently well.
  • Can participate in ordinary activities.
  • Meet school illness policies.

Viral Shedding

Prolonged shedding is not a reason for months of school exclusion.

Activity Restrictions

School attendance and sports clearance are separate decisions.

Clinical Importance

A child may be well enough to attend school before being medically ready to resume contact sports.

80. FOLLOW-UP AND MONITORING

General Principles

Follow-up should be individualized according to symptom duration and complications.

Typical Cases

Reassessment is appropriate when symptoms do not improve as expected.

Persistent Fatigue

Review:

  • Functional recovery.
  • Sleep.
  • Hydration.
  • Nutrition.
  • Alternative diagnoses.

Abnormal Liver Tests

Repeat when initially significant or clinically indicated.

Cytopenias

Monitor until improvement when clinically important abnormalities were present.

Splenic Symptoms

Investigate new abdominal pain urgently.

Immunocompromised Patients

May require prolonged specialist surveillance.

Clinical Importance

Follow-up should emphasize functional recovery and detection of complications rather than repeated EBV antibody testing.

81. PATIENT AND FAMILY EDUCATION

General Principles

Families should understand that infectious mononucleosis usually resolves without specific antiviral treatment.

Key Messages

Explain that:

  • EBV is common.
  • Many children have mild disease.
  • Fatigue may persist beyond the sore throat.
  • Antibiotics do not treat EBV.
  • Salivary transmission is possible.
  • Splenic injury is rare but serious.

Hydration

Encourage adequate fluid intake.

Activity

Avoid strenuous exercise and contact sports during the high-risk recovery period.

Warning Symptoms

Seek emergency care for:

  • Breathing difficulty.
  • Inability to drink.
  • Sudden severe abdominal pain.
  • Syncope.
  • Confusion.
  • Significant bleeding.

Clinical Importance

Education should balance reassurance with clear instructions for recognizing dangerous complications.

82. PREVENTION

General Principles

No EBV vaccine is currently available for routine clinical use.

Saliva Exposure

Avoid sharing:

  • Toothbrushes.
  • Drinks.
  • Utensils contaminated with saliva.

Kissing

Avoid direct saliva contact with symptomatic individuals when feasible.

Hand Hygiene

Encourage routine hygiene.

Contact Restrictions

Prolonged isolation is not practical because EBV shedding can continue after recovery.

Immunocompromised Patients

Require individualized exposure and infection-prevention counseling.

Clinical Importance

Prevention focuses on reducing direct saliva exposure, although complete prevention of this common lifelong infection is difficult.

83. SPECIAL CONSIDERATIONS FOR TRANSPLANT RECIPIENTS

General Principles

Pretransplant EBV serostatus is important in risk assessment.

Seronegative Recipients

May be at higher risk of PTLD following primary EBV infection after transplantation.

Viral Load Monitoring

Programs may use serial quantitative EBV PCR testing in selected high-risk recipients.

Interpretation

Viral load thresholds vary between laboratories and transplant protocols.

Treatment Decisions

May involve:

  • Adjustment of immunosuppression.
  • Further imaging.
  • Tissue biopsy.
  • Targeted treatment.

Clinical Importance

EBV management in transplantation requires established center-specific protocols rather than general mononucleosis management.

84. PROGNOSIS

General Outlook

The prognosis of primary EBV infection in immunocompetent children is excellent.

Asymptomatic Infection

Most children infected at a young age experience minimal or no recognizable symptoms.

Classic Mononucleosis

Acute symptoms generally improve over:

Two to four weeks.

Prolonged Fatigue

Fatigue may continue for several additional weeks or occasionally months.

Lymphadenopathy

Enlarged lymph nodes may resolve gradually.

Splenomegaly

Splenic enlargement may persist beyond the resolution of fever and pharyngitis.

Hepatitis

Mild liver enzyme abnormalities usually resolve spontaneously.

Recurrent Symptoms

Prolonged fatigue or other nonspecific symptoms should not automatically be attributed to active EBV infection.

Lifelong Latency

EBV remains latent after recovery.

Immunity

Primary infection generally produces long-lasting immune control and makes another primary mononucleosis episode unlikely.

Severe Complications

Prognosis depends on the affected organ and speed of treatment.

Splenic Rupture

Outcome is often favorable with prompt diagnosis and management but can be fatal if hemorrhage is not recognized.

Airway Obstruction

Usually improves with appropriate supportive or specialized treatment.

HLH

May cause significant morbidity and mortality.

Immunodeficiency

Children with impaired EBV-specific immune control have a greater risk of severe or persistent disease.

Transplant Recipients

Prognosis depends on the presence and extent of EBV-associated lymphoproliferative disease.

EBV-Associated Malignancy

Outcome depends on the specific cancer and its treatment.

Favorable Prognostic Factors

These include:

  • Immunocompetent status.
  • Adequate hydration.
  • Absence of organ-threatening complications.
  • Gradual clinical improvement.
  • Appropriate activity restriction.

Poor Prognostic Factors

These include:

  • Severe immunodeficiency.
  • HLH.
  • Severe airway compromise.
  • Splenic hemorrhage.
  • Severe neurological disease.
  • Major organ failure.

Clinical Importance

Most children recover completely, and persistent EBV antibodies after recovery are normal rather than evidence of ongoing disease.

85. COMPLICATIONS

Dehydration

Severe sore throat and reduced intake may cause fluid depletion.

Reduced Oral Intake

Painful swallowing may prevent adequate drinking and eating.

Weight Loss

Acute illness may cause temporary weight loss.

Malnutrition

Severe prolonged feeding impairment may compromise nutritional status.

Electrolyte Disturbances

Dehydration or severe illness may alter electrolyte concentrations.

Persistent Pharyngitis

Throat pain and inflammation may continue beyond the initial febrile period.

Severe Tonsillar Hypertrophy

Marked enlargement may cause obstructive symptoms.

Dysphagia

Swallowing may become difficult because of pharyngeal inflammation.

Odynophagia

Severe pain may occur during swallowing.

Muffled Voice

Extensive tonsillar swelling may alter voice quality.

Snoring

Upper airway narrowing may cause noisy sleep breathing.

Sleep-Disordered Breathing

Tonsillar enlargement may interfere with ventilation during sleep.

Upper Airway Obstruction

Severe lymphoid hyperplasia may compromise the upper airway.

Respiratory Distress

Significant obstruction may increase respiratory effort.

Hypoxemia

Severe obstruction may impair oxygenation.

Respiratory Failure

Rarely, airway compromise may require mechanical ventilation.

Emergency Airway Intervention

Severe obstruction may necessitate intubation.

Peritonsillar Abscess

Secondary bacterial infection may produce a localized collection.

Retropharyngeal Infection

Rarely, deep neck infection may coexist or develop.

Suppurative Cervical Lymphadenitis

Secondary infection may cause painful inflamed lymph nodes.

Bacterial Sinusitis

Secondary bacterial infection of the sinuses may occur.

Otitis Media

Middle ear infection may develop during a respiratory illness.

Mastoiditis

Rarely, infection may involve the mastoid structures.

Sialadenitis

Salivary gland inflammation may occur.

Persistent Cervical Lymphadenopathy

Nodes may remain enlarged for several weeks.

Generalized Lymphadenopathy

Multiple lymph node groups may become enlarged.

Splenomegaly

Lymphoid proliferation may enlarge the spleen.

Splenic Pain

Splenic capsule stretching may cause left upper abdominal discomfort.

Splenic Infarction

Rarely, compromised splenic blood flow may cause infarction.

Splenic Hematoma

Injury may produce localized splenic bleeding.

Splenic Rupture

The enlarged spleen may tear spontaneously or after trauma.

Intra-Abdominal Hemorrhage

Splenic rupture may cause major internal bleeding.

Hemorrhagic Shock

Severe bleeding may impair circulation.

Syncope

Significant blood loss may cause fainting.

Referred Left Shoulder Pain

Blood or inflammation beneath the diaphragm may produce shoulder pain.

Emergency Splenic Intervention

Selected patients may require embolization or surgery.

Splenectomy

Rarely necessary for uncontrolled hemorrhage.

Postsplenectomy Infection Risk

Children who lose the spleen require long-term protection against invasive encapsulated bacterial infections.

Hepatitis

Transient liver inflammation is common.

Transaminase Elevation

Serum ALT and AST may increase.

Hepatomegaly

The liver may become enlarged.

Cholestatic Hepatitis

Bile flow abnormalities may produce jaundice.

Hyperbilirubinemia

Bilirubin concentrations may increase during hepatitis or hemolysis.

Jaundice

Yellow discoloration may occur in more pronounced disease.

Pruritus

Cholestasis may cause itching.

Coagulopathy

Severe liver injury may impair clotting factor production.

Acute Liver Failure

Rarely, severe hepatitis may cause life-threatening hepatic dysfunction.

Autoimmune Hemolytic Anemia

EBV may trigger immune-mediated red blood cell destruction.

Cold Agglutinin-Associated Hemolysis

Cold-reactive antibodies may contribute to hemolysis.

Severe Anemia

Marked hemolysis or marrow suppression may reduce hemoglobin substantially.

Hemoglobinuria

Intravascular hemolysis may cause dark urine.

Thrombocytopenia

Platelet counts may decrease.

Severe Immune Thrombocytopenia

Occasionally, immune-mediated platelet destruction causes severe thrombocytopenia.

Petechiae

Low platelet counts may produce small skin hemorrhages.

Purpura

Bleeding into skin may produce larger purple lesions.

Mucosal Bleeding

Severe thrombocytopenia may cause epistaxis or gum bleeding.

Neutropenia

Reduced neutrophil counts may occur.

Agranulocytosis

Profound neutropenia is rare.

Pancytopenia

Multiple blood cell lines may be reduced.

Aplastic Anemia

Severe bone marrow suppression is an uncommon complication.

Hemophagocytic Lymphohistiocytosis

EBV may trigger severe systemic immune activation.

Hyperferritinemia

HLH may cause markedly elevated ferritin.

Hypofibrinogenemia

HLH-associated coagulopathy may lower fibrinogen.

Disseminated Intravascular Coagulation

Severe inflammatory disease may cause systemic coagulation abnormalities.

Multiorgan Dysfunction

HLH or severe systemic illness may impair several organs.

Aseptic Meningitis

Inflammation of the meninges may occur.

Encephalitis

EBV-associated brain inflammation may cause altered mental status or seizures.

Meningoencephalitis

Combined meningeal and brain involvement may develop.

Cerebellitis

Cerebellar inflammation may cause ataxia and coordination difficulties.

Acute Ataxia

Children may develop abnormal gait or balance.

Seizures

Neurological involvement may provoke convulsions.

Status Epilepticus

Severe neurological inflammation may cause prolonged seizures.

Encephalopathy

Systemic inflammation or direct neurological involvement may impair cognition and consciousness.

Facial Nerve Palsy

Peripheral facial weakness may occur.

Guillain-Barré Syndrome

Postinfectious immune neuropathy may cause progressive weakness.

Peripheral Neuritis

Inflammation may involve peripheral nerves.

Optic Neuritis

Rarely, optic nerve inflammation may impair vision.

Transverse Myelitis

Spinal cord inflammation may cause weakness and sensory or bladder abnormalities.

Persistent Neurological Deficits

Severe neurological disease may leave lasting functional impairment.

Myocarditis

Inflammation of the heart muscle may impair cardiac function.

Pericarditis

Inflammation may affect the pericardium.

Pericardial Effusion

Fluid may accumulate around the heart.

Cardiac Arrhythmias

Myocardial involvement may disturb heart rhythm.

Heart Failure

Severe myocarditis may reduce cardiac output.

Pancreatitis

Rarely, pancreatic inflammation may cause severe abdominal pain and vomiting.

Mesenteric Adenitis

Abdominal lymph node inflammation may cause pain.

Orchitis

Testicular inflammation is a rare complication.

Genital Ulceration

Acute non-sexually acquired genital ulcers may be associated with EBV infection.

Rash

A maculopapular eruption may occur during primary infection.

Aminopenicillin-Associated Rash

Amoxicillin or ampicillin exposure may precipitate a morbilliform eruption.

Incorrect Penicillin Allergy Label

A non-IgE-mediated eruption may lead to unnecessary lifelong avoidance of beta-lactam antibiotics.

Urticaria

Hives may occur with infection or medication exposure.

Persistent Fatigue

Fatigue may continue for weeks or months.

Postinfectious Fatigue Syndrome

A subset of patients develops prolonged functional impairment after acute illness.

Sleep Disturbance

Illness and fatigue may disrupt normal sleep patterns.

Reduced Exercise Tolerance

Physical stamina may remain limited during recovery.

School Absenteeism

Acute illness or persistent fatigue may interfere with education.

Academic Difficulties

Reduced attention or energy may affect schoolwork temporarily.

Social Withdrawal

Children may reduce participation in social activities.

Anxiety

Prolonged illness or fear of complications may cause anxiety.

Depressive Symptoms

Extended functional limitation may contribute to low mood.

Family Stress

Caregivers may experience practical and emotional burdens.

Prolonged Athletic Restriction

Sports participation may be delayed while the child recovers.

Anxiety About Splenic Injury

Athletes may be concerned about returning to training.

Invasive EBV-Associated Lymphoproliferation

Failure of immune control may permit abnormal proliferation of infected lymphocytes.

Posttransplant Lymphoproliferative Disorder

Transplant recipients may develop EBV-associated lymphoid disease.

Chronic Active EBV Disease

Rare persistent EBV-positive T- or NK-cell lymphoproliferative disease may cause serious organ involvement.

Burkitt Lymphoma

EBV is associated with certain forms of Burkitt lymphoma.

Hodgkin Lymphoma

A subset of Hodgkin lymphoma is associated with EBV.

Non-Hodgkin Lymphoma

Selected lymphomas are associated with EBV, particularly in immunocompromised populations.

Nasopharyngeal Carcinoma

EBV is strongly associated with certain nasopharyngeal carcinomas.

Other EBV-Associated Malignancies

Additional rare lymphoid or epithelial malignancies may be linked to EBV.

Primary Immunodeficiency Unmasked by EBV

Unusually severe infection may reveal an underlying immune disorder.

Fulminant EBV Disease

Children with certain inherited immune defects may develop rapidly progressive severe infection.

Transplant Graft Dysfunction

EBV-associated lymphoproliferative disease or treatment adjustments may affect graft function.

Treatment-Related Immunosuppression

Therapy for severe EBV-associated immune or lymphoproliferative disorders may increase infection risk.

Recurrent Opportunistic Infection

Immunocompromised patients may develop additional infections.

Prolonged Hospitalization

Severe complications may require extended inpatient care.

Intensive Care Admission

Airway obstruction, shock, HLH, or organ failure may require critical care.

Reduced Quality of Life

Prolonged fatigue, serious complications, or treatment burden may interfere with normal physical and social functioning.

Death

Rarely, splenic hemorrhage, severe airway obstruction, HLH, fulminant organ failure, or EBV-associated lymphoproliferative disease may result in death.


Image description
0 Comments